HIF-1α and rapamycin act as genosuppressant in multiple myeloma cells upon genotoxic stress.
Coudre C et al. Cell Cycle. 2016 Jun 24:0. [Epub ahead of print].
CA-125 secreting IgG kappa Multiple Myeloma (MM).
Boota M et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24456. [Epub ahead of print].
To B(ortezomib) or Not to B: The Stroma’s the Thing.
Krem MM et al. J Pathol. 2016 Jun 24. doi: 10.1002/path.4763. [Epub ahead of print].
A new motif for inhibitors of geranylgeranyl diphosphate synthase.
Foust BJ et al. Bioorg Med Chem. 2016 Jun 10. pii: S0968-0896(16)30442-4. doi: 10.1016/j.bmc.2016.06.019. [Epub ahead of print].
A pharmacogenetic analysis of the Canadian Cancer Trials Group (NCIC CTG) MY.10 clinical trial of maintenance therapy for multiple myeloma.
Han M et al. Blood. 2016 Jun 23. pii: blood-2016-06-716902. [Epub ahead of print].
LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients.
Shu C et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 7;1028:111-119. doi: 10.1016/j.jchromb.2016.06.009. [Epub ahead of print].
In vitro effects of a new fused azaisocytosine-like congener on relative cell proliferation, necrosis and cell cycle in cancer and normal cell cultures.
Sztanke M et al. Mol Cell Biochem. 2016 Jun 23. [Epub ahead of print].
Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models.
He D et al. Oncotarget. 2016 Jun 14. doi: 10.18632/oncotarget.9993. [Epub ahead of print].
Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.
Liu J et al. Hematology. 2016 Jun 18:1-10. [Epub ahead of print].
Adipocytes contribute to the growth and progression of multiple myeloma: unraveling obesity related differences in adipocyte signaling.
Bullwinkle EM et al. Cancer Lett. 2016 Jun 15. pii: S0304-3835(16)30370-6. doi: 10.1016/j.canlet.2016.06.010. [Epub ahead of print].
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
Overdijk MB et al.J Immunol. 2016 Jun 17. pii: 1501351. [Epub ahead of print].
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.
Storti P et al. Leukemia. 2016 Jun 17. doi: 10.1038/leu.2016.137. [Epub ahead of print].
VOLIN and KJON – Two Novel Hyperdiploid Myeloma Cell Lines.
Våtsveen TK et al. Genes Chromosomes Cancer. 2016 Jun 16. doi: 10.1002/gcc.22388. [Epub ahead of print].
Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Cytotoxic to Human Multiple Myeloma.
Jiang D et al. Mol Cancer Ther. 2016 Jun 15. pii: molcanther.1023.2016. [Epub ahead of print].
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK-cells in Patients with Myeloma.
Carlsten M et al. Clin Cancer Res. 2016 Jun 15. pii: clincanres.1108.2016. [Epub ahead of print].
CD38 levels are associated with response and complement inhibitors contribute to resistance in myelomapatients treated with daratumumab.
Nijhof IS et al. Blood. 2016 Jun 15. pii: blood-2016-03-703439. [Epub ahead of print].
Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma.
Herrero AB et al. Am J Pathol. 2016 Jun 11. pii: S0002-9440(16)30113-4. doi: 10.1016/j.ajpath.2016.04.003. [Epub ahead of print].
A new anti-CXCR4 antibody that blocks the CXCR4/SDF-1 axis and mobilizes effector cells.
Broussas M. Mol Cancer Ther. 2016 Jun 13. pii: molcanther.0041.2016. [Epub ahead of print].
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle Through Phosphoinositide 3-kinase Signaling and Ikaros Expression.
Jones RJ et al. Clin Cancer Res. 2016 Jun 13. pii: clincanres.2242.2015. [Epub ahead of print].
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Eichner R et al. Nat Med. 2016 Jun 13. doi: 10.1038/nm.4128. [Epub ahead of print].
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.
Bustany S et al. Oncotarget. 2016 Jun 7. doi: 10.18632/oncotarget.9901. [Epub ahead of print].
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
Pettus LH et al. J Med Chem. 2016 Jun 22. [Epub ahead of print].
Mechanisms of action and resistance for multiple myeloma novel drug treatments.
Iida S.Int J Hematol. 2016 Jun 9. [Epub ahead of print].
Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system.
Bonomi A et al. Hematol Oncol. 2016 Jun 10. doi: 10.1002/hon.2306. [Epub ahead of print].
Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K et al. Anticancer Drugs. 2016 Jun 7. [Epub ahead of print].
Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
Dabbah M et al. J Leukoc Biol. 2016 Jun 6. pii: jlb.3A1115-510RR. [Epub ahead of print].
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.
Bolzoni M et al. Blood. 2016 Jun 6. pii: blood-2016-01-690743. [Epub ahead of print].
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X et al. Sci Rep. 2016 Jun 6;6:26979. doi: 10.1038/srep26979.
Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.
Pagnotti GM et al. Bone. 2016 Jun 2;90:69-79. doi: 10.1016/j.bone.2016.05.014. [Epub ahead of print].
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.
Hope C et al. Blood. 2016 Jun 3. pii: blood-2016-03-705780. [Epub ahead of print].
Immuno-targeting the multifunctional CD38 using nanobody.
Li T et al. Sci Rep. 2016 Jun 2;6:27055. doi: 10.1038/srep27055.
Dual Inhibition of Mcl-1 by the Combination of Carfilzomib and TG02 In Multiple Myeloma.
Ponder KG et al. Cancer Biol Ther. 2016 May 31:0. [Epub ahead of print].
Epigenetic regulation of reelin expression in multiple myeloma.
Lin L et al. Hematol Oncol. 2016 Jun 1. doi: 10.1002/hon.2311. [Epub ahead of print].